Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05917587 · ClinicalTrials.gov registry record · Early Phase 1
Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes
A Early Phase 1 study of Gestational Diabetes, sponsored by Anna Stanhewicz, PhD.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05917587 is a Early Phase 1 study of Gestational Diabetes that is actively recruiting participants, run by Anna Stanhewicz, PhD. The registered enrollment target is 30 participants, below the 321-participant average among 41 other Gestational Diabetes trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05917587, a Early Phase 1 study of Gestational Diabetes, is actively recruiting participants, sponsored by Anna Stanhewicz, PhD.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease.
Conditions Studied
Interventions
- OTHER placebo
- DRUG Metformin Hydrochloride
Study Locations (1)
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-09-11 |
| Est. Completion | 2028-06-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05917587
The ClinicalTrials.gov registry entry for NCT05917587 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 321-participant average among 41 other Gestational Diabetes trials with a reported enrollment target (91% lower). The listed sponsor is Anna Stanhewicz, PhD, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gestational Diabetes appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT05917587 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT05917587 about?
NCT05917587 is a clinical study titled "Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes". The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease.
What is the current status of trial NCT05917587?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2024-09-11. Estimated completion is 2028-06-30.
What conditions does trial NCT05917587 study?
This clinical trial studies the following conditions: Gestational Diabetes.
What interventions are being tested in trial NCT05917587?
The interventions under investigation include: placebo (OTHER), Metformin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT05917587?
This trial is sponsored by Anna Stanhewicz, PhD, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05917587 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gestational Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM
RECRUITING · Early Phase 1
-
Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes
RECRUITING · Early Phase 1
-
Role of NADPH Oxidase in Microvascular Dysfunction Following GDM
RECRUITING · Early Phase 1
-
Soy Supplementation and Gestational Diabetes
COMPLETED · Early Phase 1
-
Nutrition Optimization and Community Upliftment for Postpartum Recovery
RECRUITING · NA
-
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.